2National Committee for Clinical Laboratory Standards. Performance standards for antimierobial susceptibility testing. 14th Inform Suppl. M100-S14. National Committee for Clinical Laboratory, Standards, Wayne, PA, 2004.
3Yahavz J, Shmuely Ho Niv Y, et al. In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagn Microbiol Infect Dis, 2006, 55:81-83.
4Heep M, Rieger U, Beck D, et al. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobaeter pylori and Mycobaeterium tuberculosis. Antimicrob Agents Chemother, 2000, 44 : 1075-1077.
5Fujimura S, Kato S, Kawamura T, et al. In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J Antimicrob Chemother, 2002, 49:541-543.
7Petra Bago,Aleksandar Vcev,Monika Tomic,Marjan Ro?ankovic,Marinko Maru?i?,Josip Bago. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial[J] 2007,Wiener klinische Wochenschrift(11-12):372～378
8Francis Mégraud MD. Update on therapeutic options for Helicobacter pylori-related diseases[J] 2005,Current Infectious Disease Reports(2):115～120
